DE60327768D1 - Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease - Google Patents

Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease

Info

Publication number
DE60327768D1
DE60327768D1 DE60327768T DE60327768T DE60327768D1 DE 60327768 D1 DE60327768 D1 DE 60327768D1 DE 60327768 T DE60327768 T DE 60327768T DE 60327768 T DE60327768 T DE 60327768T DE 60327768 D1 DE60327768 D1 DE 60327768D1
Authority
DE
Germany
Prior art keywords
drug
hiv
phenotypic
mutational profiles
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327768T
Other languages
English (en)
Inventor
Meyer Sandra De
Hilde Azijn
Bethune Marie-Pierre T M M De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Tibotec Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd filed Critical Tibotec Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE60327768D1 publication Critical patent/DE60327768D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
DE60327768T 2002-07-01 2003-06-30 Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease Expired - Lifetime DE60327768D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39275302P 2002-07-01 2002-07-01
PCT/EP2003/050277 WO2004003817A1 (en) 2002-07-01 2003-06-30 Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance

Publications (1)

Publication Number Publication Date
DE60327768D1 true DE60327768D1 (de) 2009-07-09

Family

ID=30000930

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327768T Expired - Lifetime DE60327768D1 (de) 2002-07-01 2003-06-30 Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease

Country Status (7)

Country Link
US (2) US7217506B2 (de)
EP (1) EP1520247B1 (de)
AT (1) ATE432506T1 (de)
AU (1) AU2003254500B2 (de)
CA (1) CA2490862A1 (de)
DE (1) DE60327768D1 (de)
WO (1) WO2004003817A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0011555A (pt) * 1999-05-28 2002-02-26 Virco Nv Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
WO2002033638A2 (en) * 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
WO2004003817A1 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
US7473524B2 (en) * 2002-07-01 2009-01-06 Hilde Azijn Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7372540B2 (en) * 2004-10-12 2008-05-13 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
WO2006089942A1 (en) 2005-02-25 2006-08-31 Tibotec Pharmaceuticals Ltd. Protease inhibitor precursor synthesis
EP2458018A3 (de) * 2005-05-27 2012-07-25 Monogram BioSciences, Inc. Verfahren und Zusammensetzungen zum Bestimmen der HIV-1-Beständigkeit gegenüber Proteasehemmern
CA2637203A1 (en) * 2006-01-19 2007-07-26 Monogram Biosciences, Inc. Method for determining resistance of hiv to protease inhibitor treatment
EP1987458A1 (de) * 2006-02-03 2008-11-05 Virco BVBA Quantitatives hiv-phänotyp- oder tropismus-assay

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US327742A (en) 1885-10-06 Machine for making nuts
GB2229340B (en) 1989-03-17 1994-02-09 Technophone Ltd Radio telephone system
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
EP0428000A1 (de) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
WO1993023574A1 (en) 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5685141A (en) 1995-12-26 1997-11-11 General Electric Company Lock for nozzle control in the event of hydraulic failure
ATE217971T1 (de) 1996-01-26 2002-06-15 Virco Nv Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten
JPH11502727A (ja) 1996-01-26 1999-03-09 イノジェネティックス・ナムローゼ・フェンノートシャップ 逆転写酵素遺伝子における薬剤により誘発された変異の検出方法
AP9801360A0 (en) 1996-01-29 1998-12-31 Virologic Incorporated Compositions and methods ofr determining anti-viral drug susceptibility and resistance and anti-viral drug screening.
JP3062459B2 (ja) 1996-08-14 2000-07-10 理化学研究所 ポリエステル重合酵素遺伝子及びポリエステルの製造方法
MXPA00011623A (es) 1998-05-26 2002-10-17 Virologic Inc Medios y metodos para verificar la terapia antirretroviral con inhibidor no nucleosidico de la transcriptasa inversa.
WO1999061666A1 (en) 1998-05-28 1999-12-02 Visible Genetics Inc. Use of polymorphisms as a predictor of drug-resistance mutations
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
MXPA00012843A (es) 1998-06-24 2002-04-24 Virologic Inc Medios y metodo para verificar la terapia antirretroviral con un inhibidor nucleosico de la transcriptasa inversa y guia de decisiones terapeuticas en el tratamiento del vih/sida.
AU762811B2 (en) * 1998-06-24 2003-07-03 Innogenetics N.V. Method for detection of drug-selected mutations in the HIV protease gene
BR0011555A (pt) 1999-05-28 2002-02-26 Virco Nv Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
WO2000078996A1 (en) 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
WO2000078994A1 (en) 1999-06-23 2000-12-28 The Penn State Research Foundation Compositions and methods for the quantification of sterol biosynthetic flux
WO2001079540A2 (en) * 2000-04-18 2001-10-25 Virco Bvba Methods for measuring drug resistance
CA2406830C (en) 2000-04-20 2012-10-02 Virco Bvba Method for mutation detection in hiv using pol sequencing
CA2415832C (en) 2000-06-08 2012-07-24 Brendan Larder Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
CA2422815A1 (en) 2000-09-15 2002-03-21 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU1234402A (en) 2000-10-20 2002-04-29 Virco Nv Establishment of biological cut-off values for predicting resistance to therapy
WO2002033638A2 (en) 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
JP2002199890A (ja) 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
EP1364071A2 (de) 2000-11-10 2003-11-26 Bioalliance Pharma (S.A.) Neue methode zur analyse von phänotypischen eigenschaften des humanen immunschwächevirus (hiv)
ES2275866T3 (es) 2001-02-14 2007-06-16 Tibotec Pharmaceuticals Ltd. 2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih.
US7473524B2 (en) 2002-07-01 2009-01-06 Hilde Azijn Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
US20050214744A1 (en) 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
WO2004003817A1 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
US7294642B2 (en) 2002-09-06 2007-11-13 Elan Pharmaceuticals, Inc. 1,3-Diamino-2-hydroxypropane pro-drug derivatives
EP1605064A1 (de) 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind.

Also Published As

Publication number Publication date
US7217506B2 (en) 2007-05-15
ATE432506T1 (de) 2009-06-15
AU2003254500B2 (en) 2009-11-19
US8592161B2 (en) 2013-11-26
EP1520247B1 (de) 2009-05-27
CA2490862A1 (en) 2004-01-08
WO2004003817A1 (en) 2004-01-08
EP1520247A1 (de) 2005-04-06
AU2003254500A1 (en) 2004-01-19
US20070269816A1 (en) 2007-11-22
US20050233312A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
Wu et al. Extrachromosomal DNA: an emerging hallmark in human cancer
Lythgoe et al. Shared SARS-CoV-2 diversity suggests localised transmission of minority variants
DE60327768D1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
WO2004028339A3 (en) Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
AU2002352394A1 (en) Focussed antibody technology
ATE217105T1 (de) Verfahren und vorrichtung zur unterstützung eines benutzers zum erzeugen eines medizinischen protokolls
DE60235413D1 (de) Bei prostatakrebs hochreguliertes endogenes retrovirus
Jabara et al. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection
DE60222590D1 (de) Methoden zur feststellung von akute myeloischen leukämie
Van Egeren et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein
DE60321466D1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
ES2609479T3 (es) Procedimiento implementado por ordenador y sistema informático para la identificación de organismos
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
Kim et al. Experimental malaria infection triggers early expansion of natural killer cells
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
WO2002099387A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
Mertz CRISPR Tech Behind Super-Sensitive, Smartphone COVID Test
WO2004066823A3 (en) Methods and compositions for analysis of mitochondrial-related gene expression
Lasek-Nesselquist et al. A statewide analysis of SARS-CoV-2 transmission in New York
Saha et al. Computational drug repurposing for viral infectious diseases: a case study on monkeypox
WO2005033280A3 (en) Hiv-dependent expression constructs and uses therefor
Guessous et al. Trends in pharmacogenomic epidemiology: 2001–2007

Legal Events

Date Code Title Description
8364 No opposition during term of opposition